Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Enterprise Value (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Enterprise Value over the past 3 years, most recently at -$207.6 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$207.6 million for Q4 2025, down 110.21% from a year ago — trailing twelve months through Dec 2025 was -$207.6 million (down 110.21% YoY), and the annual figure for FY2025 was -$207.6 million, down 110.21%.
  • Enterprise Value for Q4 2025 was -$207.6 million at Tonix Pharmaceuticals Holding, down from -$190.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for TNXP hit a ceiling of -$24000.0 in Q3 2024 and a floor of -$207.6 million in Q4 2025.
  • Median Enterprise Value over the past 3 years was -$48.9 million (2023), compared with a mean of -$72.6 million.
  • Biggest five-year swings in Enterprise Value: soared 99.65% in 2024 and later crashed 791795.83% in 2025.
  • Tonix Pharmaceuticals Holding's Enterprise Value stood at -$25.8 million in 2023, then crashed by 282.13% to -$98.8 million in 2024, then tumbled by 110.21% to -$207.6 million in 2025.
  • The last three reported values for Enterprise Value were -$207.6 million (Q4 2025), -$190.1 million (Q3 2025), and -$101.5 million (Q2 2025) per Business Quant data.